Find a Clinical Trial

Showing 141 - 150 of 171 Trials

  • A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05433142

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to assess whether an investigational drug called XmAb819 has any effects on Clear Cell Renal Cell Carcinoma, to determine if it is safe and well tolerated, and to determine the dosing schedule. The investigational drug will be given by intravenous (IV – into the vein) infusion over a 2 hour period. This study will also see how the body affects the study drug and how much study drug is in the blood (pharmacokinetics, or “PK”), how the drug affects the tumor and body (pharmacodynamics, or “PD”), and if the body develops antibodies...

  • A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) with oral Etoposide Administration in Children, Adolescents, and Young Adults with Progressive Diffuse Midline Glioma (DMG)

    Principal Investigator:

    Stergios Zacharoulis, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05762419

    Population:

    Pediatrics/Adult

    Phase:

    I
    Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY® microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine whether there are any clinical benefits of the study treatment. Children with progressive diffuse midline gliomas (DMGs) have very poor outcomes and have very limited options. One of the main obstacles in the effectiveness of medical...

  • A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in KRAS

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05379985

    Population:

    Pediatrics/Adult

    Phase:

    I
    The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6236 will be tested in humans. The safety of...

  • A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or RefractoryMultiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational

    Principal Investigator:

    Divaya Bhutani, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06121843

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test whether BMS-986393 in combination with other anti- cancer drugs is safe and effective at treating people with multiple myeloma (MM) that has come back after previous treatment (relapsed) or is not responding to current treatment (refractory). The researchers think that the combinations of alnuctamab, mezigdomide, or iberdomide with BMS-986393 in people with relapsed/refractory MM may improve their disease or keep their disease under control. This is an open-label, multicenter study that will recruit potential participants in the United States (USA) and...

  • An Open-Label Phase 1/2 Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06158854

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the abnormal proteins that cause amyloidosis. The study drug ABBV-383, is not approved by the U.S Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years or older - Must consent to fresh pretreatment bone marrow...

  • A Phase 1 Study of PF-08046040/SEA-CD70 in MyeloidMalignancies

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04227847

    Population:

    Adult

    Phase:

    I
    You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drug’s, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer. are testing to see if SEA- CD70 is safe for people, and its side effects. SEA-CD70 is a type of drug called an antibody. Antibodies are part of your immune system. Usually they help protect you from getting sick. The purpose of this study is to use study drug SEA-CD70, and while using another antibody...

  • CHRONIC CONVECTION ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT MALIGNANT GLIOMA

    Principal Investigator:

    Jeffrey N Bruce, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the safety of directly injecting a chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors. Currently there is no effective treatment for recurrent malignant brain tumors, which means the brain tumor has returned after the original tumor has been treated. Most systemic chemotherapy drugs have toxic side effects, which make them difficult to use for brain tumors. However, we are doing this study to find out if using an experimental method of directly infusing the drug into the tumor, allows research...

  • CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against Tcell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial

    Principal Investigator:

    Ran Reshef, MD, MSc

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06420089

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test whether Senza5 CART5 is safe to give to participants with T-cell non-Hodgkin lymphoma (NHL). The study will also test how Senza5 CART5 cells affect your cancer and how long they survive in your body. It will take some of your white blood cells, called T cells, and modify them with the hopes that they target the cancer cells or cells that help the cancer to grow. The change involves adding or altering the genes in your T cells, which are part of your immune system. The modified cell product given in this study is called Senza5 CART5. Senza5 CART5 is...

  • FORAGER-1: A Phase 1, Open-Label, Multicenter Studyof LOXO-435 (LY3866288) in Locally Advanced orMetastatic Solid Tumors Including Urothelial Cancer withFGFR3 Alterations

    Principal Investigator:

    Alexander Z. Wei, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05614739

    Population:

    Adult

    Phase:

    I
    You are being asked to participate in this study because you have cancer that is late in stage or spread to other parts of the body that includes the lining of urinary tract. The purpose of this study is to see whether LY3866288 is safe, the possible side effects, how well your disease responds to treatment study drug and which does level of study drug should be tested and is the most optimal for patients in future studies along with Pembrolizumab and Enfortumab Vedotin. LY3866288 is an investigational study drug which mean it is not approved by the United States Food and Drug Administration...

  • First-in-Human, Phase 1/1b, Open-label, Multicenter Study ofBifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapyand in Combination Therapy in Patients with EGFR-DrivenAdvanced Solid Tumors

    Principal Investigator:

    Catherine Shu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04429542

    Population:

    Adult

    Phase:

    I
    This is a first-in-human clinical research study. This study is sponsored by a biopharmaceutical company named Bicara Therapeutics. The main purpose of this study is to investigate the study drug BCA101 alone and BCA101 in combination with pembrolizumab for its safety, the way the body absorbs, distributes, and gets rid of this study drug, how the study drug acts on the body, and whether it works on your cancer in patients with advanced cancer like you. Subjects will receive either BCA101 alone or BCA101 in combination with pembrolizumab until disease worsens, the subject stops benefitting...

Pages